New York – AstraZeneca CFO Aradhana Sarin affirmed the company's steady progress towards its ambitious 2030 targets for medicines and revenue during an interview on NYSE Live. The discussion took place as the biopharmaceutical giant celebrated its recent direct listing on the New York Stock Exchange, a strategic move aimed at broadening its global investor base.
AstraZeneca has set a bold ambition to achieve $80 billion in total revenue by 2030, a significant increase from its $45.8 billion reported in 2023. This growth is anticipated to be driven by its robust existing portfolios in oncology, biopharmaceuticals, and rare diseases, alongside the planned launch of 20 new medicines before the end of the decade. CEO Pascal Soriot previously stated, "We are now aiming for $80 billion by 2030," highlighting the potential for many of these new medicines to generate over $5 billion in peak year revenues.
The company's presence on NYSE Live underscored its recent transition to a harmonized global listing structure. On February 2, 2026, AstraZeneca began trading its ordinary shares directly on the NYSE, replacing its previous American Depositary Shares (ADSs) on Nasdaq. This move, which also maintains listings on the London Stock Exchange and Nasdaq Stockholm, was lauded by NYSE Group President Lynn Martin as welcoming AstraZeneca to a "community of groundbreakers and industry leaders." The transfer marked the largest by market capitalization in the NYSE's 234-year history.
The strategic shift to the NYSE is designed to enable greater participation from U.S. investors in AstraZeneca’s growth strategy, with the U.S. being its largest market. This comes amidst a period of significant pipeline delivery and strategic partnerships, including an $18.5 billion collaboration with China's CSPC Pharmaceutical Group for weight loss and diabetes drugs.
Reflecting on the company's trajectory, CFO Aradhana Sarin stated in the NYSE Live interview, > "You mentioned our goal by 2030, in terms of medicines and revenue, we're everyday inching closer to that goal." This statement reinforces AstraZeneca's confidence in achieving its ambitious financial and product development milestones, underpinned by its innovative pipeline and expanded market access.
